AR131398A1 - Tratamiento de enfermedades autoinmunitarias - Google Patents
Tratamiento de enfermedades autoinmunitariasInfo
- Publication number
- AR131398A1 AR131398A1 ARP230103431A ARP230103431A AR131398A1 AR 131398 A1 AR131398 A1 AR 131398A1 AR P230103431 A ARP230103431 A AR P230103431A AR P230103431 A ARP230103431 A AR P230103431A AR 131398 A1 AR131398 A1 AR 131398A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- nucleic acid
- treatment
- autoimmune diseases
- pad4
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Anticuerpos para unirse a PAD y su uso en terapia. Reivindicación 1: Un anticuerpo que comprende un dominio de unión a PAD2 que se une específicamente a PAD2 y/o un dominio de unión a PAD4 que se une específicamente a PAD4. Reivindicación 97: Un polipéptido que comprende el anticuerpo de cualquier reivindicación anterior. Reivindicación 98: Un ácido nucleico que codifica una o más cadenas de un anticuerpo como se define en una cualquiera de las reivindicaciones 1 - 92. Reivindicación 99: Un ácido nucleico que codifica un polipéptido de acuerdo con la reivindicación 93. Reivindicación 100: Un vector que comprende el ácido nucleico de la reivindicación 94 o 95. Reivindicación 101: Una célula hospedadora que comprende el vector de la reivindicación 96. Reivindicación 102: Una composición farmacéutica que comprende un anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 - 92 y un portador farmacéuticamente aceptable. Reivindicación 110: Un anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 - 92 o una composición farmacéutica de acuerdo con la reivindicación 98 para su uso en un método de tratamiento o prevención de una enfermedad en un sujeto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263476066P | 2022-12-19 | 2022-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR131398A1 true AR131398A1 (es) | 2025-03-12 |
Family
ID=89474788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230103431A AR131398A1 (es) | 2022-12-19 | 2023-12-18 | Tratamiento de enfermedades autoinmunitarias |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240199761A1 (es) |
| EP (1) | EP4638507A1 (es) |
| JP (1) | JP2025542239A (es) |
| KR (1) | KR20250124877A (es) |
| CN (1) | CN120476150A (es) |
| AR (1) | AR131398A1 (es) |
| AU (1) | AU2023413552A1 (es) |
| CL (1) | CL2025001822A1 (es) |
| CO (1) | CO2025009742A2 (es) |
| CR (1) | CR20250284A (es) |
| IL (1) | IL321560A (es) |
| MX (1) | MX2025007229A (es) |
| TW (1) | TW202444762A (es) |
| WO (1) | WO2024133161A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024406222A1 (en) | 2023-12-20 | 2026-06-04 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rβ) and related methods |
| WO2026020127A2 (en) | 2024-07-19 | 2026-01-22 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad2 modulators |
| WO2026136763A1 (en) | 2024-12-19 | 2026-06-25 | Bristol-Myers Squibb Company | Genetic predictor for il18 driven disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| JPWO2012026309A1 (ja) * | 2010-08-23 | 2013-10-28 | 公立大学法人横浜市立大学 | 抗pad4抗体医薬の創成 |
| JP6057299B2 (ja) | 2011-10-31 | 2017-01-11 | 国立大学法人 長崎大学 | ウイルス感染症の予防又は治療剤 |
| CA2871934C (en) | 2012-04-30 | 2023-06-13 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| US20150376294A1 (en) | 2012-12-03 | 2015-12-31 | Rigshospitalet | Anti-pad2 antibodies and treatment of autoimmune diseases |
| AU2014374055B2 (en) | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| JP6832709B2 (ja) | 2014-05-16 | 2021-02-24 | メディミューン,エルエルシー | 新生児Fc受容体結合が改変されて治療および診断特性が強化された分子 |
| US11447569B2 (en) | 2015-03-06 | 2022-09-20 | Public University Corporation Yokohama City University | Anti-PAD4 antibody |
| WO2016155745A1 (en) | 2015-03-27 | 2016-10-06 | Rigshospitalet | Cross-reactive anti-pad antibodies |
| AR124914A1 (es) | 2021-02-18 | 2023-05-17 | Mitsubishi Tanabe Pharma Corp | Nuevo anticuerpo anti-pad4 |
-
2023
- 2023-12-18 AR ARP230103431A patent/AR131398A1/es unknown
- 2023-12-18 JP JP2025536094A patent/JP2025542239A/ja active Pending
- 2023-12-18 US US18/542,918 patent/US20240199761A1/en active Pending
- 2023-12-18 WO PCT/EP2023/086487 patent/WO2024133161A1/en not_active Ceased
- 2023-12-18 TW TW112149254A patent/TW202444762A/zh unknown
- 2023-12-18 EP EP23836387.3A patent/EP4638507A1/en active Pending
- 2023-12-18 CR CR20250284A patent/CR20250284A/es unknown
- 2023-12-18 CN CN202380087342.9A patent/CN120476150A/zh active Pending
- 2023-12-18 KR KR1020257024251A patent/KR20250124877A/ko active Pending
- 2023-12-18 AU AU2023413552A patent/AU2023413552A1/en active Pending
-
2025
- 2025-06-17 IL IL321560A patent/IL321560A/en unknown
- 2025-06-18 CL CL2025001822A patent/CL2025001822A1/es unknown
- 2025-06-19 MX MX2025007229A patent/MX2025007229A/es unknown
- 2025-07-17 CO CONC2025/0009742A patent/CO2025009742A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL321560A (en) | 2025-08-01 |
| CL2025001822A1 (es) | 2025-10-03 |
| JP2025542239A (ja) | 2025-12-25 |
| CR20250284A (es) | 2025-08-29 |
| KR20250124877A (ko) | 2025-08-20 |
| US20240199761A1 (en) | 2024-06-20 |
| CO2025009742A2 (es) | 2025-08-08 |
| MX2025007229A (es) | 2025-07-01 |
| WO2024133161A1 (en) | 2024-06-27 |
| TW202444762A (zh) | 2024-11-16 |
| CN120476150A (zh) | 2025-08-12 |
| AU2023413552A1 (en) | 2025-07-31 |
| EP4638507A1 (en) | 2025-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045056A1 (es) | Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf | |
| AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
| AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
| JOP20240279A1 (ar) | أجسام مضادة تربط إنترليوكين 13 وطرق الاستخدام | |
| MX2023002554A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| BRPI0512911A (pt) | anticorpo humano isolado, ácido nucléico, vetor, célula, método de produzir um anticorpo anti-kir humano, composição farmacêutica, e, método de potenciar a atividade da célula nk em um paciente em necessidade do mesmo | |
| BR112014029099A2 (pt) | anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende | |
| CO2022017445A2 (es) | Proteínas multiespecíficas | |
| JOP20230109A1 (ar) | أجسام مضادة ثقيلة السلسلة ترتبط مع مستقبل ألفا فولات | |
| MX2023007067A (es) | Proteinas recombinantes de union a cd3 y su uso. | |
| MX2023015469A (es) | Metodos y composiciones para estimular la actividad inmunitaria. | |
| BR112014026088A2 (pt) | produto de tratamento de tecidos, estojo, método de fabricação de um produto de tratamento de tecidos, método de tratamento, e uso do produto de tratamento de tecidos | |
| AR102595A1 (es) | Anticuerpos anti-ang2 y métodos de utilización | |
| JOP20220193A1 (ar) | صياغات من الأجسام المضادة لـ tslp البشرية وطرق لاستخدامها | |
| AR083546A1 (es) | Tratamiento de inflamacion gastrointestinal, soriasis y asma | |
| CO2022016754A2 (es) | Moléculas de fijación para el tratamiento de cáncer | |
| PE20251075A1 (es) | Anticuerpos que se unen a la pad4 humana y usos de los mismos | |
| BR112016007592A2 (pt) | proteína de ligação biespecífica que se liga a pelo menos dois alvos, conjugado de proteína de ligação biespecífica, composição farmacêutica, ácido nucleico isolado, vetor, célula hospedeira, método para produzir uma proteína de ligação biespecífica, método para determinar a reatividade de um paciente a um agente terapêutico que tem capacidade para modular a atividade de um tlr, método para ativar ou inibir células responsivas a tlr9, método para tratar um paciente que precisa de ativação de tlr9 ou inibição de tlr e método para identificar um inibidor ou estimulador de sinalização de tlr | |
| CO2025009742A2 (es) | Tratamiento de la enfermedad autoinmunitaria | |
| AR095499A1 (es) | ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b | |
| CL2025003377A1 (es) | Tratamiento de afecciones inflamatorias que comprende imu-856. | |
| MX2024001834A (es) | Metodos para tratar el cancer de vejiga no muscular invasivo (nmibc) con conjugados de anticuerpos y farmacos (adc) que se unen a las proteinas 191p4d12. | |
| PY2204506A (es) | Anticuerpos antiglicoproteína de espiga y su uso terapéutico | |
| AR104721A1 (es) | Fragmento fab anti-ngf humano |